First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment

Ozaras, ResatMete, BilgulCeylan, BahadirOzgunes, NailGunduz, AlperKaraosmanoglu, HayatCagatay, AtahanGokturk, KadirErdem, LeventKocak, FundaSenates, EbubekirTABAK, Ömer Fehmi2020-10-222020-10-222014-07-01Ozaras R., Mete B., Ceylan B., Ozgunes N., Gunduz A., Karaosmanoglu H., Cagatay A., Gokturk K., Erdem L., Kocak F., et al., -First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment-, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.26, ss.774-780, 2014http://hdl.handle.net/20.500.12645/24438Background Hepatitis B virus (HBV) infection is a health problem worldwide. Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons. Tenofovir and entecavir are much more commonly used as they have better efficacy, tolerability, and high genetic barriers to resistance.First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatmentArticleWOS:0003371513000138490213129710.1097/meg.000000000000009924901822